Tumor immunotherapy has been limited to date by the poor antigenicity of most tumors, the
immunocompromised state of many cancer patients, and the slow tumor penetration and
short half-life of exogenously-introduced anti-tumor antibodies. Our group has developed a
model immunotherapy system using a chimeric construct containing an antibody V region
fused to a T cell activation molecule (T body) introduced by transfection into cytotoxic T cell
lines, or populations of activated primary T or natural killer (NK) cells. In this study we have …